Tetherex Pharmaceuticals IPO

tetherex.com

Developer of drugs for the treatment of inflammatory and thrombotic diseases. The company's treatment program is built around an antibody called SelK2 directed against the cell adhesion molecule P-Selectin Glycoprotein Ligand-1 (PSGL-1).

Founded2002
Total Funding to Date$68.65MM
Register for Details

For more details on financing and valuation for Tetherex Pharmaceuticals, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Tetherex Pharmaceuticals Ticker Symbol

Tetherex Pharmaceuticals does not currently have an official ticker symbol because this company is still private. Register today to connect with our Private Market Specialists and learn more about new pre-IPO investment opportunities.

Tetherex Pharmaceuticals Stock Price

The stock price for Tetherex Pharmaceuticals will be known as it becomes public. Here are similar public companies: HealthStream (NAS: HSTM), Doximity (NYS: DOCS), Zymergen (NAS: ZY), Sight Sciences (NAS: SGHT).

Tetherex Pharmaceuticals Funding Rounds and IPO Valuation

Date Funding Round Funding Raised Price per Share IPO Valuation
4/18/2018 Series B $366.68MM $XXX.XX $XXX.XX
2/9/2015 Series A $11.73MM $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data

Other companies like Tetherex Pharmaceuticals in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$317.32MM
Sector
 
 
Sector
Last Round Est. Valuation
$1.59B
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$334.19MM